Ocugen Shares Drop 7.2% Despite Positive Outlook

Biotech firm faces short-term volatility as investors parse mixed financials and development updates

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Ocugen, Inc. (NASDAQ:OCGN) saw its share price drop 7.2% on Thursday, closing at $1.8180. The decline came despite positive sentiment around the company's regulatory plans and clinical milestones, including a 2026 BLA submission and three pivotal filings expected within three years, as well as the completion of enrollment for a Phase 3 trial of its gene therapy for retinitis pigmentosa.

Why it matters

Ocugen's stock movement reflects the short-term volatility that can occur as investors evaluate the company's mixed financial results and development updates. While the positive regulatory and clinical news could drive long-term value, the current quarter's negative revenue and substantial losses have put near-term pressure on the stock.

The details

Ocugen reported a Q4 2025 EPS loss of $0.06, in line with expectations, but revenue came in at -$0.19 million, substantially below the estimated $0.86 million. The quarter showed a $17.7 million loss with very negative margins and return on equity, which can weigh on the stock until the company's revenue and expense trends improve.

  • Ocugen outlined plans for a 2026 BLA submission and expects three pivotal filings within three years.
  • Enrollment for the OCU400 Phase 3 liMeliGhT trial (gene therapy for broad retinitis pigmentosa) is complete, with topline Phase 3 data expected in Q1 2027.

The players

Ocugen, Inc.

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.